

# Oregon Prescription Drug Affordability Board

350 Winter Street NE, Salem, OR 97309-0405 | 971-374-3724 | [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov) | [dfr.oregon.gov/pdab](http://dfr.oregon.gov/pdab)

## Agenda

Date: August 3, 2022 | Time: 9:30 a.m.

**Amended**

<b>Meeting name</b>	<b>Prescription Drug Affordability Board</b>	<b>Board Members:</b> Akil Patterson, Chair; Shelley Bailey, Vice Chair; Daniel Hartung; Richard Bruno; Robert Judge (A); Rebecca Spain (A) *(A) denotes Alternate Member <b>Staff:</b> Ralph Magrish, executive director; Cortnee Whitlock, policy analyst; Stephen Kooyman, project manager; Melissa Stiles, administrative specialist; Joanna Tucker Davis, counsel; Pramela Reddi, counsel
<b>Meeting location</b>	Virtual	
<b>Zoom link</b>	<a href="#">Click here to register for the meeting</a>	

Subject	Presenter	Time Allotted
<input type="checkbox"/> Call to order, roll call and <a href="#">approval of minutes</a>	Chair Patterson	5 minutes
<input type="checkbox"/> Executive Director's program update	Ralph Magrish	5 minutes
<b>PDAB Policies and Procedures:</b>		
<input type="checkbox"/> <a href="#">PDAB Draft Conflict of Interest Policy and Form</a> <a href="#">PDAB Draft Public Comment Policy and Form</a> – updated <a href="#">Proposed Work Plan</a> – updated	Cortnee Whitlock	20 minutes
<input type="checkbox"/> <ul style="list-style-type: none"> <li>• Review of Required Topics for Report Outline</li> <li>• Distinguishing between recommendations in Sec 5 &amp; 7 (SB 844)</li> <li>• Discussion of Additional Topics for Reports</li> <li>• Next steps</li> <li>• Approval of Roadmap</li> </ul>	PDAB Staff	45 minutes
<input type="checkbox"/> Announcements	Ralph Magrish	5 minutes
<input type="checkbox"/> Public comment	Chair Patterson	10 minutes
<input type="checkbox"/> Adjournment	Chair Patterson	2 minutes

## Next Meeting

August 17, 2022, at 9:30 a.m.

## Accessibility

The meeting is accessible to persons with disabilities. A request for hearing impaired assistance and accommodations for persons with disabilities may be made to Melissa Stiles by email at [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov) or by phone at 971-374-3724, with at least 48 hours' notice.

## Public Comment

### **Verbal Testimony**

To sign up for public comment, email your request to the Prescription Drug Affordability Board at [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov) 24 hours before the meeting. Include your name, organization, and the related agenda item.

### **Written Testimony**

Email your written testimony to the Prescription Drug Affordability Board at [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov) 72 hours prior to scheduled meeting. Any written comments after 72 hours will be included for board consideration at the next meeting. Include your name, organization, and the related agenda item.

## Open and Closed Sessions

All board meetings except executive sessions are open to the public. Pursuant to ORS 192.660, executive sessions are closed, with the exception of news media and staff. No final actions will be taken in the executive session. When action is necessary, the board will return to an open session.



**Oregon Prescription Drug Affordability Board Virtual Meeting  
Wednesday, July 20, 2022  
Draft Minutes**

**Call to Order and Roll Call**

Chair Akil Patterson called the meeting to order at 9:04 a.m. and called roll.

**Board Members and Alternate Members Present:** Shelley Bailey, Richard Bruno, Akil Patterson.

**Board Members Absent:** Dr. Daniel Hartung (excused)

**Alternates Present:** Robert Judge, Rebecca Spain (arrived at 9:20am)

**Approval of the Minutes**

Chair Akil Patterson asked if board members had any changes to the June 23, 2022, minutes on Pages 3-6 in the packet posted online: <https://dfr.oregon.gov/pdab/Documents/20220720-PDAB-document-package.pdf>.

Hearing none, the chair asked for a motion to approve the minutes. Vice Chair Shelley Bailey moved to approve, and Dr. Bruno provided a second.

**MOTION by Shelley Bailey to approve the recommended board appointments.**

**Board Roll Call Vote:**

Yea: Shelley Bailey, Richard Bruno, Akil Patterson, Robert Judge.

Nay: None.

**Motion passed.**

**Executive Session**

The chair announced the board's adjournment to the executive session for legal advice pursuant to ORS 192.660(2)(h). The meeting was not open to the public except for the media and staff. No votes were taken.

**Return to Open Session**

The board returned to open session, and a roll call was taken. Shelley Bailey, Richard Bruno, Robert Judge, and Akil Patterson were present.

**Program Update**

Executive Director Ralph Magrish said the board added an August 3 meeting to discuss the Proposed Work Plan further. The National Academy for State Health Policy's Drug Pricing Center put out a request for a proposal for technical assistance for states with PDABs to support initiatives. Oregon looks forward to the opportunity to access that technical assistance this fall. The Colorado PDAB released draft affordability criteria at its July 15 meeting. The Oregon PDAB will look closely at the process and find ways to leverage lessons learned for Oregon.

The executive director let the board know about a recent report from the Cost Growth Target (CGT) Program housed at the Oregon Health Authority (OHA), a program with which the Oregon PDAB has a legislative reporting requirement with. According to the report, between 2013 and 2019, pharmacy costs per person rose from \$633 to \$1365 per year. The information source is Oregon All Payer All Claims Reporting Program. On the Medicaid side, pharmacy increased by 79 percent, from \$794 to \$2261 per person. This is pre-rebate information, and more evaluation of the data about cost and utilization will be informative, he said. PDAB staff has meetings with the CGT team about the data and upcoming deliverables.



Vice Chair Shelley Bailey asked if the data about post-rebate dollars would be available. Executive Director Magrish said it might be available through the Oregon All Payer All Claims Reporting Program. The vice chair said it is a meaningful part of the analysis and hopes the board can take advantage of it during reviews.

### **PDAB Policies and Procedures**

**PDAB Policy Amended:** Board Policy Analyst Cortnee Whitlock brought back an amended PDAB policy approved by the board on June 23. The conflict of interest policy has been assigned a policy number and will be discussed at the August 3 board meeting. She reviewed the proposed changes on Pages 7-11 of the agenda packet posted here: <https://dfr.oregon.gov/pdab/Documents/20220720-PDAB-document-package.pdf>. In Section 10, staff added verbiage based on board feedback that the chair will select a voting member from the alternate members. She said that as soon as the board approves this amended policy, the chair can ask an alternate to vote. Section 11 changes a word from “may” to “will” regarding executive sessions for trade secrets. She scrolled through the remaining changes and said this amended policy would require a board vote.

Chair Patterson asked about the board voting on an amended policy before the board formalizes the conflict of interest policy. Cortnee Whitlock said the conflict of interest policy had been assigned a number, 03, and a placeholder has been included in the main policy. She said the board could table this portion until the next meeting. Chair Patterson thanked the staff for the clarification. The chair asked for any board discussion, and there was none. The chair called for a motion to accept the PDAB policy amendments, and Dr. Bruno so moved. Vice Chair Shelley Bailey provided a second. Chair Patterson asked for a roll call vote.

### **MOTION by Richard Bruno to approve the PDAB policy amended.**

#### **Board Roll Call Vote:**

Yea: Shelley Bailey, Richard Bruno, Akil Patterson.

Nay: None.

#### **Motion passed.**

During the roll call vote, the board secretary called on Alternate Member Robert Judge before his appointment by the chair as a voting member due to the absence of member Daniel Hartung. DOJ Counsel Joanna Tucker Davis recommended Robert Judge withdraw his vote, which Robert Judge did. After the policy approval vote, Chair Patterson assigned voting rights to Robert Judge for the remainder of the meeting.

**PDAB Draft Delegation Policy:** Cortnee Whitlock, board policy analyst, said the draft delegation policy was presented at the June 23 meeting and tabled for further review. The policy’s purpose is to clarify when staff may perform work on behalf of the Prescription Drug Affordability Board and to provide guidance to the board regarding their duties and responsibilities. She reviewed the draft delegation policy on Pages 12-15 of the agenda packet posted here: <https://dfr.oregon.gov/pdab/Documents/20220720-PDAB-document-package.pdf>. In Section 3, language was added that third-party contractors are to disclose any conflict of interest prior to a contract agreement, and if any conflicts arise during the time of the contract, contractors will tell the staff so staff can let board members know. In Section 4, the primary update is in the contracting section and removed language that is not relevant in Oregon.

Chair Patterson acknowledged Dr. Rebecca Spain’s arrival to the meeting. The chair asked for a motion. Dr. Bruno moved to approve the policy with the changes as described, and Vice Chair Bailey provided a second. He asked for any board discussion, and there was none. Chair Patterson asked for a roll call vote. The chair noted again that Robert Judge has voting authority during today’s meeting.



**MOTION by Shelley Bailey to approve the PDAB Delegation Policy.**

**Board Roll Call Vote**

Yea: Richard Bruno, Shelley Bailey, Akil Patterson, Robert Judge.

Nay: None.

**Motion passed.**

**Presentation of Proposed Work Plan**

Project Manager Stephen Kooyman presented the proposed work plan to the board. He scrolled through the plan located on Pages 16-21 of the agenda packet posted here:

<https://dfr.oregon.gov/pdab/Documents/20220720-PDAB-document-package.pdf>. He said staff would present the plan today and bring it back to the Board for approval at the next meeting. He reviewed the board meeting schedule, timelines for annual studies and reports, and rules development. Cortnee Whitlock reviewed the goals on the 2022 roadmap and draft for the 2023 roadmap, including drug affordability reviews. The generic drug marketplace report is the first of four reports due at the end of the year. Affordability review criteria development and adoption of rules should be completed by June 1, 2023, and affordability reviews will not be completed until December 31, 2023.

Chair Patterson asked if Oregon passed an insulin policy last year. Director Magrish said Oregon instituted a cap on insulin for small group plans, impacting only about a quarter of Oregonians and did not impact Oregon Health Plan (OHP) members who are not subject to copays for prescriptions. Vice Chair Bailey asked if the 2023 focus is on generic medications only or will brand name medications be part of the board's cost analysis. Cortnee Whitlock said both would be reviewed. Ralph Magrish said there are separate legislative deliverables, one for a generic-specific marketplace report and one for an overall cost prescription drugs report.

**Announcements**

Ralph Magrish introduced TK Keen, administrator of the Division of Financial Regulation. Ralph Magrish said the two data analytics staff positions have been reposted. Application links can be found on the PDAB website: <https://dfr.oregon.gov/pdab/Pages/index.aspx>. The recruitment closed for the rural representative for the vacant board and alternate positions. Recommendations have been submitted to the governor's office and may be announced by August. The candidates will go through confirmation hearings September 21-23, in time for the October PDAB meeting.

Chair Patterson said the next meeting is August 3, 2022 at 9:30 a.m. He said the meeting is accessible to persons with disabilities. A request for hearing impaired assistance and accommodations for persons with disabilities may be made to Melissa Stiles by email at [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov) or by phone at 971-374-3724. He said to sign up for public comment, email the request to the Prescription Drug Affordability Board at [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov) 24 hours before the meeting. Include name, organization, and related agenda item. For written comments, submit 72 hours prior to scheduled meeting. Any written comments after 72 hours will be included for board consideration at the next meeting.

**Public Comment**

The Chair asked if any public comment requests were received 24 hours before the meeting. Staff confirmed no requests were received. The chair said someone had a hand raised in the meeting but because of stated guidance in the agenda on testimony sign-up had not been followed, the chair encouraged that person to submit a request to provide verbal testimony 24 hours before the August 3 meeting or submit written testimony 72 hours before the August 3 meeting. He said people are welcome to submit written comment anytime to the PDAB office.



**Adjournment**

There being no further business before the Board, the chair asked for a motion to adjourn the meeting at 9:53 a.m. Dr. Richard Bruno moved to adjourn, and Vice Chair Bailey provided a second.

**MOTION by Richard Bruno to adjourn the meeting.**

**Board Roll Call Vote**

Yea: Akil Patterson, Shelley Bailey, Richard Bruno, Dr. Rebecca Spain, Robert Judge.

Nay: None.

**Motion passed.**

DRAFT

**Prescription Drug Affordability Board**  
**Policy Number: 03-DRAFT PENDING BOARD APPROVAL**

**Title:** Conflict of Interest Policy and Procedure

**Date Issued:**

**Dates Reviewed:**

**Date Adopted:**

**1. Purpose**

To ensure that the Oregon Prescription Drug Affordability Board (Board) conducts business for the benefit of the public and in the absence of personal, financial, or otherwise improper interests. The purpose of this policy is to describe the statutory requirements regarding conflicts of interest.

**2. ORS Chapter 244**

Board members will adhere to the requirements of ORS chapter 244, the Government Ethics Act, and the Oregon Administrative Rules, chapter 199, of the Oregon Government Ethics Commission (OGEC), which can be found here:

<https://secure.sos.state.or.us/oard/displayChapterRules.action?selectedChapter=143>

Guidance regarding these laws can be found on the OGEC website:

<https://www.oregon.gov/ogec/Pages/default.aspx>

Board members will disclose, in accordance with subsection 4 of this policy, any potential or actual conflicts of interest as defined in ORS 244.020(1) and (13):

- (1) “Actual conflict of interest” means any action or any decision or recommendation by a person acting in a capacity as a public official, the effect of which would be to the private pecuniary benefit or detriment of the person or the person’s relative or any business with which the person or a relative of the person is associated unless the pecuniary benefit or detriment arises out of circumstances described in subsection (13) of this section.”
- (13) “Potential conflict of interest” means any action or any decision or recommendation by a person acting in a capacity as a public official, the effect of which could be to the private pecuniary benefit or detriment of the person or the person’s relative, or a business with which the person or the person’s relative is associated, unless the pecuniary benefit or detriment arises out of the following:
  - (a) An interest or membership in a particular business, industry, occupation or other class required by law as a prerequisite to the holding by the person of the office or position.
  - (b) Any action in the person’s official capacity which would affect to the same degree a class consisting of all inhabitants of the state, or a smaller class consisting of an

industry, occupation or other group including one of which or in which the person, or the person's relative or business with which the person or the person's relative is associated, is a member or is engaged.

- (c) Membership in or membership on the board of directors of a nonprofit corporation that is tax-exempt under section 501(c) of the Internal Revenue Code.”

Board members, under ORS 244.120(2), will also:

- (a) When met with a potential conflict of interest, announce publicly the nature of the potential conflict prior to taking any action as a Board member; or
- (b) When met with an actual conflict of interest, announce publicly the nature of the actual conflict and:
  - (A) Except as provided in subparagraph (B) of this paragraph, refrain from participating as a Board member in any discussion or debate on the issue out of which the actual conflict arises or from voting on the issue.
  - (B) If the Board Member's vote is necessary to meet a requirement of a minimum number of votes to take official action, be eligible to vote, but not to participate as a public official in any discussion or debate on the issue out of which the actual conflict arises.

*Please note that if the requirements of recusal under ORS 646A.693 apply, the Board member must recuse themselves from the decision, even if the Board member would otherwise be allowed to vote under ORS 244.120(2)(b)(B).*

### **3. ORS 646A.693**

Board members will adhere to the requirements of ORS 646A.693 as follows:

#### **Recusal**

- (a) A member of the board shall recuse the member from decisions related to a prescription drug if the member, or an immediate family member of the member, has received or could receive any of the following:
  - (A) A direct financial benefit of any amount deriving from the result or finding of a study, review or determination by or for the board; or
  - (B) A financial benefit from any person that owns, manufactures, or provides prescription drugs, services or items to be reviewed by the board that in the aggregate exceeds \$5,000 per year.
- (b) For the purposes of paragraph (a) of this subsection, a financial benefit includes honoraria, fees, stock, the value of the member's or immediate family member's stock holdings and any

direct financial benefit deriving from the result or finding of a study, review or determination by or for the board.

### **Disclosure of Conflicts of Interest**

- (c) A conflict of interest shall be disclosed:
  - (A) By the board when hiring board staff;
  - (B) By the Governor when appointing members and alternate members to the board; and
  - (C) By the board, when a member of the board is recused in any final decision resulting from a review of a prescription drug.
- (d) A conflict of interest shall be disclosed at the earlier of:
  - (A) Prior to the first board meeting after the conflict is identified; or
  - (B) Within five days after the conflict is identified.
- (e) A conflict of interest disclosed under this section shall be posted on the website of the board unless the chairperson of the board recuses the member from any final decision resulting from a review of a prescription drug.
- (f) A posting under paragraph (e) of this subsection shall include the type, nature and magnitude of the conflict of interest of the member involved.

### **Gifts**

Members and alternate members of the Board, staff, and third parties that contract with the Board may not accept any gift or donation of services or property that creates a potential conflict of interest or has the appearance of biasing the work of the Board.

## **4. Procedures for Identifying and Managing Conflicts of Interest**

Prior to each Board meeting, Board Members will review the draft agenda and identify any potential or actual conflicts of interest under ORS 646.120 or ORS 646A.693 (conflict of interest).

When a Board Member determines they have a conflict of interest, the Board Member must inform the Board Chair and Vice-Chair, recuse themselves and fill out and submit the Conflict of Interest form to [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov).

The Board Member will also notify the board staff to help ensure that the Member does not have access to information on matters for which the Member must recuse themselves and to ensure the conflict of interest is appropriately posted.

Potential contractors will disclose any prior or current work in the pharmaceutical business sector that could give rise to a potential or actual conflict of interest as defined in ORS 244.020.

Contractors will ensure that qualified personnel selected to perform work for the Board have no professional, familial or financial conflict of interest relating to the pharmaceutical business sector. In connection with any particular project or work to be performed, the Board reserves the right to reject any proposed personnel. In the event the Board rejects the proposed personnel, the contractor will be required to provide other personnel who are acceptable to the Board.

## **5. Annual Review**

The Board will review this policy at least annually.

DRAFT



## Prescription Drug Affordability Board

### CONFLICT OF INTEREST FORM

The Prescription Drug Affordability Board (PDAB) asks that you complete this Conflict of Interest disclosure requirements in ORS Chapter 244.

This form is due annually, when a conflict is disclosed by a Board Member under ORS 646A.693, or when a conflict is disclosed by a contractor under ORS 244.020. You may wish to retain a copy of this form.

**Instructions:** Please fill in the appropriate box. If a conflict of interest is indicated fill out questions 1 through 4 and include activities occurring currently or during the past year. Return by email to: [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov)

Declaration (check one):

- I confirm that neither I nor any immediate family member nor any business with which I am associated have any personal or business interest in or potential for personal gain from any of the organizations or projects linked to PDAB. I also confirm that the disclosed information is correct and that no other situation of real, potential or apparent conflict of interest is known to me. I undertake to inform the Board Chair of any conflict or potential conflict of which I become aware immediately following any announcement by the Board or the PDAB Staff which may concern me. I also undertake to inform the Board Chair of any change in these circumstances, including – if an issue arises – during the course of my association with PDAB as a Board Member, board staff, contractors, and assigned Assistant Attorneys General.
- I confirm that I or my immediate family member have a financial or other interest in the subject/matter of the work in which I will be involved, which may be considered as constituting a real, potential or apparent conflict of interest.

*If this section is checked please answer the following questions.*

#### 1. Financial Benefit

If you or an Immediate Family Member (see definition below) have a direct or indirect ownership or investment, or can benefit from any person that owns, manufactures, or provides prescription drugs, please note the name of the source, ownership percentage and any income generated from the ownership or investment interest. Financial benefit includes honoraria, fees, stock, the value of the member’s or Immediate Family Member’s stock holdings and any direct financial benefit deriving from the result or finding of a study, review or determination by or for the board.

Name & Address of Source	Financial Benefit	Received By


**Immediate Family Member** - Means any person living in the same household as a Board Member, a staff member, and/or a contractor working on behalf of the Board.

Does an income source listed above do business, or could it reasonably be expected to do business, with the public body you wish to serve or over which you may have authority? **Yes**  **No**

Does an income source listed above have a legislative or administrative interest in the public body you wish to serve or over which you may have authority? **Yes**  **No**

**2. SHARED BUSINESS WITH LOBBYIST**

If you or a member of your household shared a partnership, joint venture, or similar substantial economic relationship with a paid lobbyist during the immediately preceding calendar year, or were employed by or employed a paid lobbyist during that time, please list the following: (Note: owning stock in a publicly traded company in which the lobbyist also owns stock is not a relationship which requires disclosure):

Name of Lobbyist	Business Name	Business Type

_____	_____
<b>Name</b>	<b>Date</b>
_____	
<b>Signature</b>	
<b>Please return by email to: <a href="mailto:pdab@dcbs.oregon.gov">pdab@dcbs.oregon.gov</a></b>	

## Prescription Drug Affordability Board

Policy Number: **04-DRAFT PENDING BOARD APPROVAL**

**Title:** Public Comment

**Date Issued:**

**Dates Reviewed:**

**Date Adopted:**

### 1. Purpose

The opportunity for public comment will be provided at each Prescription Drug Affordability Board meeting.

### 2. Policy Statement

The Prescription Drug Affordability Board welcomes public comment during Board meetings. Board members generally will not respond to public comments during a meeting. Public comments may be submitted in writing or given orally during the designated time by completing the PDAB Public Comment form provided on the PDAB website.

The form's purpose is 1) to sign up to provide comments, 2) to assist board staff with time allotments for meeting agenda items, and 3) to disclose interest or affiliation.

Having an interest or affiliation does not prevent written or oral comments from being provided, but is included on the form for transparency purposes. Prior to the public comment, the Board Chair will state whether the form has been completed and any interest or affiliation of the speaker.


#### Written Comments

The Board will receive written public comments and the PDAB Public Comment form through the Prescription Drug Affordability Board at [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov). The form includes fields for the name, organization and topic item for persons submitting written testimony. Written public comments submitted less than 72 hours before a board meeting will be considered at the following meeting.

#### Oral Comments

Persons interested in providing oral public comments may sign up by completing the PDAB Public Comment form and emailing it to [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov) no later than 24 hours before the meeting. Anyone who did not sign up before the deadline will have the opportunity to speak at the next meeting after completing the PDAB Public Comment form. Speakers will be called to speak in the order in which they sign up. The Board Chair will ask the speakers to introduce themselves with their name and affiliation if any.

The amount of time allocated for oral public comment will be determined by the Board Chair in consultation with Board staff. When there are multiple requests to comment on a particular topic, the Board Chair may limit or expand the total time for comment or reduce the time allotted for each speaker. Any changes will be announced at the beginning of the public comment agenda item.



# PDAB Public Comment Form

The purpose of this form is to sign up to provide public comment orally or in writing and to disclose an interest or affiliation. Having an interest or affiliation does not prevent written or oral comments from being provided, but is included on the form for transparency purposes. Failure to complete this form does not disqualify a speaker from commenting, however, persons who opt not to complete the form should be advised it will be publicly stated prior to their public comment commencing.

**Instructions:** Please read all information. Questions marked with an asterisk (\*) are required fields. Please email the form for public comment to [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov) no later than 24 hours before the PDAB meeting. If providing written comments, please fill out this form and email it to [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov) no later than 72 hours before PDAB meeting. If you need assistance completing or emailing this form, please call the PDAB office at 971-374-3724 or send an email to [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov).

## COMMENTER INFORMATION

*Name:	*Date:
*Organization, if applicable:	*Topic/Drug:
Email Address:	Phone Number:
Are written comments submitted with this form? <span style="float: right;">Yes <input type="checkbox"/> No <input type="checkbox"/></span>	
*Are you an employee of a Pharmaceutical manufacturer, pharmaceutical trade association, or other trade association? (If <b>yes</b> , please skip to the last question) <span style="float: right;">Yes <input type="checkbox"/> No <input type="checkbox"/></span>	
*Are you an advocate or advocacy organization that receives funding from a Pharmaceutical manufacturer <b>OR</b> a foundation that receives funding from Pharmaceutical entities? <span style="float: right;">Yes <input type="checkbox"/> No <input type="checkbox"/></span>	
*Have you been asked to provide comments by any advocacy group or Pharmaceutical entity? <span style="float: right;">Yes <input type="checkbox"/> No <input type="checkbox"/></span> *If <b>yes</b> , please identify the entity / organization:	
*If you are a researcher or clinician, do you currently receive grants or other funding from any advocacy or Pharmaceutical entity? <span style="float: right;">Yes <input type="checkbox"/> No <input type="checkbox"/></span> *If <b>yes</b> , please identify the entity:	
*Are you involved in or have you been involved in any research funded directly or indirectly from any advocacy or Pharmaceutical entity? <span style="float: right;">Yes <input type="checkbox"/> No <input type="checkbox"/></span> *If <b>yes</b> , please describe the type of compensation:	
Is there any other information about yourself that the Board should know (e.g. direct ownership and control of investments in a Pharmaceutical manufacturer, etc.)?	



Oregon Prescription Drug  
Affordability Board




# Prescription Drug Affordability Board

Proposed Work Plan  
2022 - 2023


# Proposed Work Plan

PDAB's work plan tracks the milestones and deliverables need to support the board's responsibilities:

- Board Meeting Schedule
- Annual Studies
- Annual Reports
- Rules Development



# Board Meetings through 2022



# Board Meetings and Topics



## TOPICS

Work Plan	July 20 PDAB Meeting	Aug. 3 PDAB Meeting	Aug. 17 PDAB Meeting	Sept. 21 PDAB Meeting	Oct. 19 PDAB Meeting	Nov. 16 PDAB Meeting	Dec. 14 PDAB Meeting	Report Due Date
	Presentation to Board		Formal Approval					
Review Rx Report from DPT				Presentation for Board Review				
Rx Generic Drugs Report <sup>1</sup>								12/31/22
Rx Distribution and Payment System Report				Presentation of Outline to Board	Presentation of First Draft to Board	Presentation of Second Draft to Board	Board Approval of Final Draft	12/31/22
Price Trends for List of Rx								12/31/22
Recommendations from Rx List								12/31/22
Report of Affordability Reviews Conducted by the Board <sup>2</sup>								06/01/23

<sup>1</sup>Originally due June 1, now December 31, 2022

<sup>2</sup>Originally due December 31, 2022, now due June 1, 2023



# PDAB ROADMAP for 2022

## Review Reports from DPT

- Rx list of Carriers
- New Rx list of Manufactures

## Studies

- Rx Distribution and Payment System
- Generic Drugs
- Price trends for list of Rx
- Recommendations from Rx list

## Draft Annual Reports

- Rx Distribution and Payment System
- Generic Drugs
- Price trends for list of Rx
- Recommendations from Rx list

## Rules

- Develop Structure:
- Fee Structure
  - Affordability Criteria

## Rules

- Present Proposed Structures:
- Fee Structure
  - Affordability Criteria

## Identify 9 Rx & Insulin

Review list for 2023 review

## Annual Reports Due

- Rx Distribution and Payment System
- Generic Drugs
- Price trends for list of Rx
- Recommendations from Rx list

JAN

FEB

MAR

Q1

APR

MAY

JUN

Q2

JUL

AUG

SEP

Q3

OCT


NOV

DEC

Q4



# PDAB ROADMAP for 2023



# Rx Generic Drugs Report (SB 844, Section 6 (2))

Annually by June 1, the Board conducts a study of the operation of the US market for generic drugs, both drugs dispensed by pharmacists and drugs administered by physicians, including:

1. The prices of generic drugs on a year-to-year basis
2. The degree to which generic drug prices affect insurance premiums
3. Annual changes in health insurance cost-sharing for generic drugs
4. The potential for and history of generic drug shortages
5. The degree to which generic drug prices affect annual spending in the state medical assistance program
6. Any other topic the board considers relevant to the cost of generic drugs

For 2022 reporting, Section 6 (2) will be submitted to the Legislative Assembly by 12/31/2022.



Oregon Prescription Drug  
Affordability Board



# Rx Distribution and Payment System Report (SB 844, Section 7)

(1) Study of the entire prescription drug distribution and payment system in Oregon and policies adopted by other states and countries that are designed to lower the list price of prescription drugs including but not limited to the following options:

- (a) Establishing upper payment limits for all financial transactions in this state involving a drug and specifying the methodology used to determine the upper payment limit that does not undermine the viability of any part of the prescription drug supply chain;
- (b) Using a reverse auction marketplace for the purchase of prescription drugs by state and local governments;
- (c) Implementing a bulk purchasing process for state and local governments to purchase prescription drugs.

(2) No later than December 31, 2022, PDAB shall report to the interim committees of the Legislative Assembly:

- (a) The board's findings including findings for each option described in subsection (1) of this section; and
- (b) Recommendations for policies to lower the list prices of prescription drugs sold in this state and for legislative changes necessary to implement the policies.



# SB 844, Section 5 (1) & (3)

By December 31 of each year, the PDAB shall report to the Health Care Cost Growth Target program and to the interim committees of the Legislative Assembly.

For 2022, Section 5 (1) and (3) will be reported by 12/31/2022. Section 5 (2), for the prescription drugs that were reviewed under Section 2 of SB 844, will be reported by 06/01/2023.

(1) Price trends for the list of prescription drugs provided to the board by the Department of Consumer and Business Services

(3) Recommendations, if any, for legislative changes necessary to make prescription drug products more affordable in this state.



# Section 5 vs Section 7 Recommendations

## Section 5 (3)

PDAB to provide recommendations if any, for legislative changes necessary to make prescription drug products more affordable in this state.

## Section 7 (2)

Recommendations for policies to lower the list prices of prescription drugs sold in this state and for legislative changes necessary to implement the policies.



# What are additional topics to include?



# Next Steps

Send any reporting suggestions to  
[pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov)

August 17<sup>th</sup> Presentation of Outline  
for PDAB reports

